Nvidia Corp. is set to invest $1 billion over five years in collaboration with Eli Lilly & Co. to accelerate the incorporation of artificial intelligence in the pharmaceutical sector.
The new facility will be established in Silicon Valley, bringing Lilly’s laboratory expertise closer to the heart of AI innovation, Nvidia announced on Monday, January 12. The project is described as a joint investment, although specific financial details were not disclosed.
This initiative aims to enhance a traditionally lengthy process that heavily depends on human researchers conducting physical experiments.
The investment exemplifies Nvidia’s strategic use of its significant financial resources to foster new markets for its products. As the world’s most valuable company, Nvidia leads the market for artificial intelligence accelerators—chips essential for developing and running AI models. However, a few major tech clients constitute a large portion of its revenue.
Nvidia perceives the health care and pharmaceutical sectors as promising areas for its technology. Companies are increasingly leveraging AI to generate innovative concepts for new drugs or compounds, though verification through laboratory experiments is still necessary. Nvidia contends that AI can automate much of this process.
“Humans are the primary constraint on the speed of labs,” stated Kimberly Powell, Nvidia’s vice president of health care.
Also Read: Amid a surge in AI memory demand, SK Hynix is set to invest $13 billion in a new chip packaging facility.
The joint laboratory will enable AI engineers to understand the operations of lab equipment and research tasks. Subsequently, they will assist the pharmaceutical company in refining computers and software to handle some responsibilities typically assigned to human operators.
In addition to the lab, Nvidia is broadening its array of AI models and agents specifically designed for the health care sector, making them open source. This allows anyone to modify the technology to suit their requirements.
The company is also collaborating with Thermo Fisher Scientific Inc. to integrate laboratory equipment with Nvidia’s DGX Spark AI computer, facilitating automated management of lab activities. Furthermore, it is partnering with Multiply Labs to educate robots on research protocols, planning for a future where facilities can operate autonomously.
This partnership positions Lilly at the forefront of AI-driven drug discovery, a field still in its infancy with no major breakthroughs to date.
The agreement builds on an earlier collaboration between the two companies, which announced in October their goal to create the “most powerful supercomputer owned and operated by a pharmaceutical company.” This supercomputer, located at Lilly’s headquarters in Indianapolis, is expected to be fully operational by the first quarter.
Lilly employees will collaborate closely with Nvidia staff to ensure “seamless collaboration and access to world-class scientific and technical talent,” a spokesperson for Lilly stated. Initially, the innovation lab will focus on drug discovery and AI model development, according to the company.
